Quick Answer
OnKure Therapeutics, Inc. reported R&D Expense of $48.26 million for fiscal year 2025.
OnKure Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $48.26M | +10.2% |
| 2024 | $43.80M | +36.4% |
| 2023 | $32.12M | -14.8% |
| 2022 | $37.70M | +33.9% |
| 2021 | $28.17M | +76.7% |
| 2020 | $15.94M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.91M | +17.8% | -5.5% |
| June 30, 2025 | $12.61M | +17.3% | -3.1% |
| March 31, 2025 | $13.01M | +51.9% | +28.6% |
| September 30, 2024 | $10.12M | -25.7% | -5.9% |
| June 30, 2024 | $10.75M | -25.3% | +25.5% |
| March 31, 2024 | $8.57M | -22.1% | -37.1% |
| September 30, 2023 | $13.62M | +37.1% | -5.4% |
| June 30, 2023 | $14.40M | +77.1% | +31.0% |
- OnKure Therapeutics, Inc. showed an increase of +10.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, OnKure Therapeutics, Inc.’s r&d expense has grown by 202.7% (from $15.94 million to $48.26 million).
- The most recent figure is from OnKure Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: